The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

EBMT 2018 | Reducing GvHD with FMS-like receptor tyrosine kinase 3 ligand treatment of bone marrow donors 

Mar 22, 2018

Plasmacytoid dendritic cells (pDC) in donor grafts showed increased survival and reduced graft-versus-host disease (GvHD) in recipients of bone marrow (BM), but not in recipients receiving granulocyte-colony stimulating factor peripheral blood grafts.

Mojibade Hassanfrom Emory University, Atlanta, GA, presented results of a study examining FMS-like receptor tyrosine kinase 3 ligand (Flt3L) treated BM (F-BM) and pDC’s effect on transplant outcomes in a murine transplant model at the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)in Lisbon, Portugal.

Methods:

  • Mice were treated with 300ug/kg of Flt3L on Days -1 and -4
  • Cell counts of pDC and HSC in murine F-BM grafts were analyzed by flow cytometry

Key findings:

  • Flt3L improved pDC content (3–fold) and HSC content (1.5–fold) in BM grafts
  • In recipients of untreated BM with T-cells, transplantation of Flt3L treated BM with untreated T-cells improved survival from 45% to 75%
  • Flt3L treated BM grafts with T-cells increased survival in a tumor model to 60% compared with survival of mice transplanted with untreated BM grafts, which had a survival of 30%

Hassan concluded her talk by stating that Flt3L treatment of bone marrow donors significantly increased survival and decreased GvHD. Additionally, F-BM grafts increased survival in a murine tumor model. To conclude, the speaker highlighted that “upregulation of adaptive immune pathways and downregulation of toll-like receptor cascades in Flt3L treated bone marrow grafts may play a role in attenuation of GvHD post transplant.”

  1. Hassan M.  et al.  FMS-like receptor tyrosine kinase 3 ligand treatment of bone marrow donors increase survival and GvT in allo-BMT recipients while reducing GvHD in murine transplant model. Abstract OS3-6. 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT). 2018 Mar 19.